Diagnostic use of radiolabeled antibodies for cancer.
Antibodies against a variety of tumor-associated antigens have been studied, as well as a number of modifications to the antibodies themselves, including Fab' fragments and chimeric, humanized, and human antibodies. The appropriate use of radioimmunoconjugates in the evaluation of cancer patients has not yet been clearly defined. Only a few studies have assessed their use, primarily through the intravenous route, in initial disease staging. To date, immunolymphoscintigraphy has not proven promising in the staging of cancers. More emphasis has been given to the use of IV radioimmunoconjugates to detect residual and recurrent disease, with generally favorable results. In addition, radioimmunoguided surgery, using small, handheld probes to detect foci of antibody accumulation, appears to be a valuable tool. As better production techniques become available and large clinical trials provide more clearly defined indications for radioimmunoconjugate use, these agents should enter the arena for routine diagnostic use.
Harrison
K A
KA
Department of Radiology, University of Nebraska Medical Center, Omaha 68198-1045, USA.
Tempero
M A
MA
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007205:Indium Radioisotopes; D009369:Neoplasms / Q000000981:diagnostic imaging*; D009842:Oligopeptides; D004369:Pentetic Acid / Q000031:analogs & derivatives; D016719:Radioimmunodetection
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C063430:Indium 111In-satumomab pendetide; D007205:Indium Radioisotopes; D009842:Oligopeptides; D004369:Pentetic Acid